Loading...
Header Logo
Keywords
Last Name
Institution

SHERRY WU

TitleAssistant Professor
InstitutionMD Anderson
DepartmentGynecological Oncology & Reproductive Medicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Shi S, Li T, Wen X, Wu SY, Xiong C, Zhao J, Lincha VR, Chow DS, Liu Y, Sood AK, Li C. Copper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention. Bioconjug Chem. 2019 Oct 16; 30(10):2675-2683. PMID: 31560538.
      View in: PubMed
    2. McGuire MH, Herbrich SM, Dasari SK, Wu SY, Wang Y, Rupaimoole R, Lopez-Berestein G, Baggerly KA, Sood AK. Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells. EBioMedicine. 2019 May; 43:127-137. PMID: 31056473.
      View in: PubMed
    3. Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK. GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther. 2019 05; 18(5):969-979. PMID: 30926640.
      View in: PubMed
    4. Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK. Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. Mol Cancer Ther. 2019 02; 18(2):421-436. PMID: 30420565.
      View in: PubMed
    5. Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther. 2019 01; 18(1):162-172. PMID: 30305341.
      View in: PubMed
    6. Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AK. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun. 2018 07 26; 9(1):2923. PMID: 30050129.
      View in: PubMed
    7. Gharpure KM, Lara OD, Wen Y, Pradeep S, LaFargue C, Ivan C, Rupaimoole R, Hu W, Mangala LS, Wu SY, Nagaraja AS, Baggerly K, Sood AK. ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget. 2018 May 18; 9(38):25115-25126. PMID: 29861857.
      View in: PubMed
    8. Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AK. Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res. 2018 06 15; 78(12):3233-3242. PMID: 29661830.
      View in: PubMed
    9. Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AK. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017 Dec 05; 21(10):2785-2795. PMID: 29212026.
      View in: PubMed
    10. Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046. PMID: 28855350.
      View in: PubMed
    11. Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Nov 14; 8(57):96496-96505. PMID: 29228548.
      View in: PubMed
    12. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2017 Aug 17; 2(16). PMID: 28814667.
      View in: PubMed
    13. Lyons YA, Wu SY, Overwijk WW, Baggerly KA, Sood AK. Immune cell profiling in cancer: molecular approaches to cell-specific identification. NPJ Precis Oncol. 2017; 1(1):26. PMID: 29872708.
      View in: PubMed
    14. Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein G. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Mol Ther Nucleic Acids. 2017 Dec 15; 9:251-262. PMID: 29246304.
      View in: PubMed
    15. Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Sood AK. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst. 2017 07 01; 109(7). PMID: 28376174.
      View in: PubMed
    16. Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Huang-Hobbs E, Haemmerle M, Wu SY, McGuire M, Protopopov A, Jiang S, Liu JF, Hirsch MS, Chang Q, Lazar AJ, Sood AK, Drapkin R, DePinho R, Draetta G, Chin L. PRKCI promotes immune suppression in ovarian cancer. Genes Dev. 2017 06 01; 31(11):1109-1121. PMID: 28698296.
      View in: PubMed
    17. Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, Rodriguez-Aguayo C, Zhang X, Coleman RL, Lopez-Berestein G, Sood AK. Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol Cancer Ther. 2017 06; 16(6):1114-1123. PMID: 28265009.
      View in: PubMed
    18. Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodríguez-Aguayo C, López-Berestein G, Ju-Seog L, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo M. HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer. Mol Cancer Ther. 2017 05; 16(5):966-976. PMID: 28223424.
      View in: PubMed
    19. Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Jennings N, Shim J, Dorniak PL, Mangala LS, Petrillo M, Petyuk VA, Schepmoes AA, Shukla AK, Torres-Lugo M, Lee JS, Rodland KD, Fagotti A, Lopez-Berestein G, Li C, Sood AK. Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Rep. 2016 11 01; 17(6):1621-1631. PMID: 27806300.
      View in: PubMed
    20. Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, Zhang Z, Sood AK, Ordog T, Bitler BG, Zhang R. BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Res. 2016 11 01; 76(21):6320-6330. PMID: 27803105.
      View in: PubMed
    21. Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight. 2016 Oct 20; 1(17):e87754. PMID: 27777972.
      View in: PubMed
    22. Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest. 2016 05 02; 126(5):1885-96. PMID: 27064283.
      View in: PubMed
    23. Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun. 2016 Apr 04; 7:11169. PMID: 27041221.
      View in: PubMed
    24. Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK. Role of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst. 2016 Jan 26; 108(6):djv426. PMID: 26819345.
      View in: PubMed
    25. Hatakeyama H, Wu SY, Mangala LS, Lopez-Berestein G, Sood AK. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol. 2016; 1402:189-197. PMID: 26721492.
      View in: PubMed
    26. Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NMZ, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Kovacs J, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AK. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Rep. 2015 Dec 22; 13(11):2395-2402. PMID: 26686630.
      View in: PubMed
    27. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and Challenges of Liposome Assisted Drug Delivery. Front Pharmacol. 2015; 6:286. PMID: 26648870.
      View in: PubMed
    28. Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 2015 Nov 09; 28(5):610-622. PMID: 26481148.
      View in: PubMed
    29. Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GE. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 2015 Oct 06; 6(30):29161-77. PMID: 26313360.
      View in: PubMed
    30. Gharpure KM, Wu SY, Li C, Lopez-Berestein G, Sood AK. Nanotechnology: Future of Oncotherapy. Clin Cancer Res. 2015 Jul 15; 21(14):3121-30. PMID: 26180057.
      View in: PubMed
    31. Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein G. The ZNF304-integrin axis protects against anoikis in cancer. Nat Commun. 2015 Jun 17; 6:7351. PMID: 26081979.
      View in: PubMed
    32. Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AK. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clin Cancer Res. 2015 Jul 15; 21(14):3286-97. PMID: 25878333.
      View in: PubMed
    33. Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AK. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2014 Oct 29; 5:5202. PMID: 25351346.
      View in: PubMed
    34. Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK. Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther. 2014 Dec; 13(12):2876-85. PMID: 25281617.
      View in: PubMed
    35. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14; 26(1):77-91. PMID: 25026212.
      View in: PubMed
    36. Wu SY, Lopez-Berestein G, Calin GA, Sood AK. RNAi therapies: drugging the undruggable. Sci Transl Med. 2014 Jun 11; 6(240):240ps7. PMID: 24920658.
      View in: PubMed
    37. Rytelewski M, Tong JG, Buensuceso A, Leong HS, Maleki Vareki S, Figueredo R, Di Cresce C, Wu SY, Herbrich SM, Baggerly KA, Romanow L, Shepherd T, Deroo BJ, Sood AK, Chambers AF, Vincent M, Ferguson PJ, Koropatnick J. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. Mol Oncol. 2014 Dec; 8(8):1429-40. PMID: 24974076.
      View in: PubMed
    38. Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AK. Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther. 2014 Jul; 13(7):1750-7. PMID: 24755199.
      View in: PubMed
    39. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93. PMID: 24743243.
      View in: PubMed
    40. Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014 Mar 12; 5:3459. PMID: 24619206.
      View in: PubMed
    41. Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, Lopez-Berestein G, Sood AK, Afshar-Kharghan V. Autocrine effects of tumor-derived complement. Cell Rep. 2014 Mar 27; 6(6):1085-1095. PMID: 24613353.
      View in: PubMed
    42. Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J, Eskiocak B, Chung H, McMillan E, Wu S, De Brabander J, Komurov K, Toombs JE, Wei S, Peyton M, Williams N, Gazdar AF, Posner BA, Brekken RA, Sood AK, Deberardinis RJ, Roth MG, Minna JD, White MA. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell. 2013 Oct 24; 155(3):552-66. PMID: 24243015.
      View in: PubMed
    43. Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 02; 105(19):1485-95. PMID: 24062525.
      View in: PubMed
    44. Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013 Nov; 3(11):1302-15. PMID: 24002999.
      View in: PubMed
    45. Masiero M, Simões FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, Li JL, Patient R, Sood AK, Banham AH, Harris AL, Buffa FM. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013 Aug 12; 24(2):229-41. PMID: 23871637.
      View in: PubMed
    46. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427. PMID: 24018975.
      View in: PubMed
    47. Wu SY, Sood AK. New roles opined for OPCML. Cancer Discov. 2012 Feb; 2(2):115-6. PMID: 22585855.
      View in: PubMed
    48. Singhania A, Wu SY, McMillan NA. Effective Delivery of PEGylated siRNA-Containing Lipoplexes to Extraperitoneal Tumours following Intraperitoneal Administration. J Drug Deliv. 2011; 2011:192562. PMID: 21773042.
      View in: PubMed
    49. Khairuddin N, Gantier MP, Blake SJ, Wu SY, Behlke MA, Williams BR, McMillan NA. siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol. 2012 Feb; 90(2):187-96. PMID: 21423261.
      View in: PubMed
    50. Wu SY, Chang HI, Burgess M, McMillan NA. Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system. J Control Release. 2011 Nov 07; 155(3):418-26. PMID: 21315117.
      View in: PubMed
    51. Wu SY, McMillan NA. Lipidic systems for in vivo siRNA delivery. AAPS J. 2009 Dec; 11(4):639-52. PMID: 19757082.
      View in: PubMed
    52. Wu SY, Putral LN, Liang M, Chang HI, Davies NM, McMillan NA. Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use. Pharm Res. 2009 Mar; 26(3):512-22. PMID: 19023647.
      View in: PubMed
    53. Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology. 6.
    54. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. Journal of Clinical Investigation. 126:1885-1896.
    55. Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Reports. 17:1621-1631.
    56. Assessment of In vivo siRNA delivery in cancer mouse models. 189-197.
    57. Role of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute. 108.
    58. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene.
    59. BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer. Cancer Research. 76:6320-6330.
    60. The use of lipid-based nanocarriers for targeted pain therapies. Frontiers in Pharmacology. 4 NOV.
    61. Lowering the sirna delivery barrier. 193-216.
    62. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications. 7.
    63. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 6:29161-29177.
    64. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports. 13:2395-2402.
    65. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene.
    66. The ZNF304-integrin axis protects against anoikis in cancer. Nature Communications. 6.
    67. Nanotechnology. Clinical Cancer Research. 21:3121-3130.
    68. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 28:610-622.
    69. XPO1/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5A. Clinical Cancer Research. 21:3286-3297.
    WU's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description